drugset / Trial / NCT01615445

Resveratrol Supplementation on Exercise in Healthy Sedentary Adults

NCT01615445

Phase 2 Completed 13 enrolled Ottawa Hospital Research Institute
RandomizedCrossoverQuadruple-blindBasic science

Summary

Previous animal studies have found that resveratrol supplementation significantly increased aerobic capacity. The investigators conducted a randomized placebo-controlled cross-over study to assess whether resveratrol could provide similar benefits in humans. All participants were assigned to two 4-week treatment periods, with a 2 week washout in-between. During one period, volunteers in received resveratrol and during the other period, they received identical-appearing placebo. The primary outcome of interest was change in exercise capacity, as measured by change in exercise duration on constant load exercise testing and change in aerobic capacity (peak VO2) on incremental exercise testing. Secondary outcomes were tolerability and side-effects associated with resveratrol.

Timeline

Start
2009-02
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Resveratrol Small molecule 1000 mg

Indications

No indication recorded.